Holly Schachner

Dr. Schachner joined the board of directors in August 2021. Dr. Schachner has been the Chief Medical Officer of DoubleRainbow Biosciences, Inc. since August 2021. From September 2020 to April 2021, she served as Senior Vice President, Clinical Science Therapeutic Area Head at MyoKardia, Inc., a clinical-stage biopharmaceutical company focused on therapies for serious cardiovascular diseases, until it was acquired by Bristol Myers Squibb. Prior to MyoKardia, Dr. Schachner worked at Allergan plc, a pharmaceutical company, as the Chief Medical Officer of Global Specialty Medicine from March 2019 to July 2020. Prior to Allergan, Dr. Schachner worked at Sanofi, a biopharmaceutical company, including as the US Medical Chair and North America Medical Head, Diabetes & Cardiovascular Business Unit from 2016 to 2019 and Vice President and Head of Cardiovascular Medical Unit, North America from 2014 to 2016. Dr. Schachner holds a B.S. in Psychology from the University of Michigan, an M.D. from Stony Brook School of Medicine, and completed a pediatric residency and pediatric endocrinology fellowship at the Mount Sinai Medical Center in New York.